30 / 40
PARP inhibitors as maintenance in ovarian cancer relapse
Agenda
•
Biomarkers and development of PARPi in ovarian cancer
•
Overview of efficacy outcomes by biomarkers cohorts
•
Long-term benefit
•
Safety profile and quality of life
•
Future of PARP inhibitors as maintenance in recurrence setting